Novo Nordisk’s Wegovy Gets EU Backing to Treat Obesity-Related Heart Failure
Novo Nordisk said European regulators support the use of its blockbuster weight-loss drug Wegovy to help reduce heart failure in obese patients.The Danish pharmaceutical giant said late Thursday that the European Medicines Agency backing came after the regulator also recently approved Wegovy’s use to lower the risk of heart attacks and strokes in overweight or obese adults without diabetes,